NEW YORK, NY / ACCESSWIRE / April 23, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided.
AVEO Pharmaceuticals, Inc. (AVEO)
Class Period: August 4, 2016 - January 31, 2019
Lead Plaintiff Deadline : April 26, 2019
Join the action: https://www.zlk.com/pslra-1/aveo-pharmaceuticals-inc-loss-form?prid=1241&wire=1
Allegations: AVEO Pharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the TIVO‑3 trial was inadequately designed to address the OS concerns regarding AVEO's lead candidate drug, tivozanib, from the TIVO-1 trial presented in June 2013; (ii) tivozanib had insufficient survival data to meet FDA approval following its initial 2013 rejection; (iii) this lack of sufficient survival data would put tivozanib at greater risk of delayed FDA approval; and (iv) as a result, AVEO's public statements were materially false and misleading at all relevant times.
To learn more about the AVEO Pharmaceuticals, Inc. class action contact email@example.com.
Diplomat Pharmacy, Inc. (DPLO)
Class Period: February 26, 2018 - February 21, 2019
Lead Plaintiff Deadline : April 25, 2019
Join the action: https://www.zlk.com/pslra-1/diplomat-pharmacy-inc-loss-form?prid=1241&wire=1
Allegations: Diplomat Pharmacy, Inc. made materially false and/or misleading statements throughout the class period and/or failed to disclose that: (1) Diplomat had downplayed its success in integrating and growing its PBM business, which included LDI Integrated and National Pharmaceutical, two companies Diplomat had acquired in late 2017; (2) consequently, Diplomat would need to record a non-cash impairment charge upwards of approximately $630 million relating to its PBM business and these 2017 acquisitions; (3) due to the foregoing, Diplomat would withdraw its preliminary 2019 full-year outlook issued less than seven weeks prior; and (4) as a result, defendants' statements about Diplomat’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
To learn more about the Diplomat Pharmacy, Inc. class action contact firstname.lastname@example.org.
Sprint Corporation (NYSE:S)
Class Period: January 31, 2019 - April 16, 2019
Lead Plaintiff Deadline : June 21, 2019
Join the action: https://www.zlk.com/pslra-1/sprint-corporation-loss-form?prid=1241&wire=1
The complaint alleges that Sprint made materially false and misleading statements and/or failed to disclose material information. In particular, the complaint alleges that throughout the class period Sprint misrepresented the number of net postpaid subscriber additions in its Form 10-Q for the period ending December 31, 2018. Sprint would later admit that the data was ''incomplete,'' and ''not a substitute for a realistic analysis of the key factors that are most probative of Sprint's overall competitive position and prospects,'' because ''postpaid net additions recently have been driven by ‘free lines' offered to Sprint customers and the inclusion of less valuable tablet and other non-phone devices, as well as pre to post migrations that do not represent ‘new' Sprint customers.''
To learn more about the Sprint Corporation class action contact email@example.com.
You have until the lead plaintiff deadlines to request the court appoint as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com: